1. Biomarker-Guided HF Therapy: Is It Cost-Effective?

2. Age-Adjusted Hospitalization Rates for Heart Failure

3. Cost* of Heart Failure to Society

4. Diagnostic Uncertainty Is Associated With Poor Prognosis in Acute Dyspnea

6. Effect of Selective NT-proBNP Testing on Costs Results of the Randomized IMPROVE-CHF Trial

7. ADHERE: Time From BNP to Time to Diuretic Treatment

8. OPTIMIZE-HF BNP Measures and Death and Hospitalization at 1 Year

9. Therapies With Effects on B-Type Natriuretic Peptide Levels

10. IMPROVE HF: Improvement in Quality Measures at 24 Months (Patient Level Analysis)

11. PROTECT: Primary Endpoint Reduction

12. Cost-Effectiveness TIME-CHF Mortality in Reduced LVEF

13. Biomarker -Guided Heart Failure Trials

14. GUIDE-IT

15. Challenges/Opportunities for Utilizing Biomarkers in the Management of Heart Failure

16. Thank you for joining us for this program. So, what would you do
Thank you for joining us for this program. So, what would you do? What impact does this program on biomarkers have on your practice? As a reminder please join me on Medscape Discuss, a supplementary discussion by clicking the Join the Discussion  button now. I am interested in hearing your thoughts and questions around this topic.